For the quarter ending 2026-03-31, VVOS made $5,141K in revenue. -$7,682K in net income. Net profit margin of -149.43%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 5,141 | 3,824 | 6,783 | 3,820 |
| Cost of sales (exclusive of depreciation and amortization shown separately below) | 2,082 | 838 | 2,846 | 1,710 |
| Gross profit | 3,059 | 2,986 | 3,937 | 2,110 |
| General and administrative | 8,971 | 8,542 | 7,884 | 6,409 |
| Sales and marketing | 249 | 379 | 403 | 260 |
| Depreciation and amortization | 454 | 442 | 384 | 306 |
| Total operating expenses | 9,674 | 9,363 | 8,671 | 6,975 |
| Operating loss | -6,615 | -6,377 | -4,734 | -4,865 |
| Other expense | -1,167 | -635 | -679 | -163 |
| Other income | 31 | 59 | 13 | 15 |
| Loss before income taxes | -7,751 | -6,953 | -5,400 | -5,013 |
| Net loss | -7,751 | -6,908* | - | - |
| Net loss attributable to non-controlling interest | -69 | -15* | - | - |
| Net loss attributable to stockholders | -7,682 | -6,893 | -5,400 | -5,013 |
| Basic EPS | -0.52 | -0.554 | -0.49 | -0.55 |
| Diluted EPS | -0.52 | -0.554 | -0.49 | -0.55 |
| Basic Average Shares | 14,634,115 | 12,449,444 | 10,963,590 | 9,087,202 |
| Diluted Average Shares | 14,634,115 | 12,449,444 | 10,963,590 | 9,087,202 |
Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc. (VVOS)